THALES
Eseye, a global IoT connectivity solutions provider, has selected Thales to accelerate and simplify worldwide IoT deployment with a seamless connectivity solution. Thales pioneering solution enables Eseye to automatically connect IoT devices with the most appropriate profile the first time they are powered up and in-life. Thales Adaptive Connect (TAC) based on eSIM (embedded SIM) technology that drastically simplifies the management of IoT devices lifecycle. It is the first market-ready solution that eliminates the need to configure mobile subscriptions in the factory, or for technicians to visit them in the field.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228389495/en/
@Thales
Eseye provides IoT cellular connectivity services worldwide, and TAC brings connectivity management of IoT devices remotely to make it far easier for its customers to roll-out and support major projects in areas such as: smart utilities, supply chains, logistics, and automotive. Indeed, any kind of IoT device can be deployed and connected in any region or country without being configured beforehand.
TAC is remotely managing the eSIM automatic configuration to provide the best local connectivity from its first usage and throughout its lifespan on the field. With Thales, Eseye can ensure they all connect to the preferred mobile network whenever it is needed. For example, deployed IoT devices can be switched to another mobile network remotely, over-the-air, at any time. The Thales solution fully complies with GSMA eSIM IoT standard SGP.32, ensuring security, reliability, and future proof capability for massive IoT use cases.
Thanks to the Thales connectivity offer for eSIM-based devices, Eseye will be able to operate and manage flexible, end-to-end connectivity from the factory to the field, and throughout the device lifecycle. Which means the entire operation, including manufacturing, logistics, and connectivity, is streamlined and simplified.
“Eseye are delighted to be partnering with Thales to take forward this leading-edge, innovative new IoT solution. Combining SGP.32 and SGP.41 support will ensure future IoT device deployments can deliver optimum efficiency and value to our customers. Not only do Enterprise customers get a completely future proofed eSIM platform, but it also enables maximum choice of either personalising devices for local mobile networks ahead of deployment or using TAC to do this for them in the field” said Adam Hayes, Chief Operating Officer at Eseye.
"Eseye is a dynamic partner with whom we have also worked on a Proof of Concept for customers interested in in-factory provisioning (IFPP) for their devices. This enables profiles to be securely provisioned during the device manufacturing process. For example, a blood sugar monitor device that has been configured at the factory will have a substantially longer battery life since there is no need for an in-field local profile download. This solution, which meets the latest market specifications (SGP.41), retains all of the benefits of an automatic and cost-effective connection to the preferred local network," said Guillaume Lafaix, VP of Connectivity Solutions and Embedded Products at Thales.
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity. Thales has 77,000[1] employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. [1] Excluding the Transport business |
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228389495/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom